HomeCompareVCRA vs PFE

VCRA vs PFE: Dividend Comparison 2026

VCRA yields 2.53% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $26.1K in total portfolio value· pulled ahead in Year 9
10 years
VCRA
VCRA
● Live price
2.53%
Share price
$79.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.5K
Annual income
$297.54
Full VCRA calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — VCRA vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVCRAPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VCRA + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VCRA pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VCRA
Annual income on $10K today (after 15% tax)
$214.84/yr
After 10yr DRIP, annual income (after tax)
$252.91/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,066.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VCRA + PFE for your $10,000?

VCRA: 50%PFE: 50%
100% PFE50/50100% VCRA
Portfolio after 10yr
$36.5K
Annual income
$13,278.13/yr
Blended yield
36.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

VCRA
Analyst Ratings
13
Buy
13
Hold
Consensus: Buy
Price Target
$46.00
-41.9% upside vs current
Range: $46.00 — $46.00
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VCRA buys
0
PFE buys
0
No recent congressional trades found for VCRA or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVCRAPFE
Forward yield2.53%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$23.5K$49.6K
Annual income after 10y$297.54$26,258.71
Total dividends collected$2.8K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$46.00$27.50

Year-by-year: VCRA vs PFE ($10,000, DRIP)

YearVCRA PortfolioVCRA Income/yrPFE PortfolioPFE Income/yrGap
1$10,953$252.75$9,153$693.39+$1.8KVCRA
2$11,978$258.72$8,593$849.25+$3.4KVCRA
3$13,081$264.43$8,336$1,066.78+$4.7KVCRA
4$14,267$269.89$8,437$1,384.80+$5.8KVCRA
5$15,540$275.09$9,013$1,875.40+$6.5KVCRA
6$16,908$280.05$10,306$2,680.72+$6.6KVCRA
7$18,377$284.76$12,820$4,101.38+$5.6KVCRA
8$19,952$289.25$17,673$6,826.70+$2.3KVCRA
9← crossover$21,642$293.50$27,543$12,591.86$5.9KPFE
10$23,455$297.54$49,560$26,258.71$26.1KPFE

VCRA vs PFE: Complete Analysis 2026

VCRAStock

Vocera Communications, Inc. provides secure, integrated, and intelligent communication and workflow solutions that empowers mobile workers in healthcare, hospitality, retail, energy, education, and other mission-critical mobile work environments in the United States and internationally. The company's communication solution integrates with other clinical systems, including electronic health records, nurse call systems, and patient monitoring, as well as to provide critical data, alerts, alarms, and clinical context that enable workflow. It also offers Vocera Communication and Workflow System, a software platform, which connects communication devices, such as hands-free, wearable, and voice-controlled Smartbadge and badges, as well as third-party mobile devices; and Vocera Care Experience, a hosted software suite that coordinates and streamlines provider-to-patient and provider-to-provider communication and clinical rounding to enhance quality of care, patient and staff experience, reduce care provider's risk, and improve reimbursements, as well as Vocera Ease, a cloud-based communication platform and mobile application to enhance the patient experience by enabling friends and family members to receive timely updates about the progress of their loved one in the hospital. In addition, the company provides professional, software maintenance, and technical support services; and classroom training, distance learning, or customized courseware for systems administrators, IT and industry-specific professionals, and end-user educators. As of December 31, 2020, the company provided its solutions to approximately 1,900 healthcare facilities, including large hospital systems, small and medium-sized local hospitals, clinics, surgery centers, and aged-care facilities. It sells its products through direct sales force, resellers, and distributors. The company was incorporated in 2000 and is headquartered in San Jose, California.

Full VCRA Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this VCRA vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VCRA vs SCHDVCRA vs JEPIVCRA vs OVCRA vs KOVCRA vs MAINVCRA vs JNJVCRA vs MRKVCRA vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.